Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
June 06, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries
May 22, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals annonce l’approbation par Santé Canada de IMCIVREE® setmélanotide pour injection pour la prise en charge du poids en présence du syndrome de Bardet-Biedl ou d’un déficit biallélique en POMC, PCSK1 ou LEPR.
May 08, 2023 09:00 ET
|
Rhythm Pharmaceuticals, Inc.
– Il s’agit du premier et seul traitement approuvé au Canada, qui cible la déficience génétique de la voie MC4R, une cause profonde d’apparition précoce de l’obésité sévère chez ces patients – ...
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency
May 08, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- First and only approved therapy in Canada that targets genetic impairment in the MC4R pathway - a root cause of early-onset, severe obesity in these patients – -- Approval granted following a...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 05, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
May 02, 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Strong U.S. commercial progress continues for IMCIVREE® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received since FDA approval -- -- Launched...
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
April 24, 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
April 18, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...